P/B
0,3
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
$46.6M
Market Cap • 11/6/2026
2025
(1 year ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
12,5
EPS
—
Market Cap
Market Cap
46,6M
EV
-87,6M
EV/Revenue
0
EV/EBITDA
1,5
EV/EBIT
1,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-212,9%
Total Yield
-212,9%
Payout
0%
Retained Earnings
-250,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
1,5%
CAGR Net Income 5Y
-0,8%
CAGR EPS 5Y
-52,5%
CAGR OCF 5Y
1,4%
Leverage
N.D./EBITDA
2,3
Debt/Equity
0%
Current Ratio
21,5
Quick Ratio
20,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!